Pancreatic β-Cell KATP Channel Activity and Membrane-Binding Studies with Nateglinide: A Comparison with Sulfonylureas and Repaglinide
The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
Nateglinide (A-4166) is an amino acid derivative with insulinotrophic action in clinical development for treatment of type 2 diabetes. The aim of this study was to determine whether nateglinide's interaction at the K ATP channel/sulfonylurea receptor underlies its more rapid onset and shorter duration of action in animal models. Binding studies were carried out with membranes prepared from RIN-m5F cells and HEK-293 cells expressing recombinant human sulfonylurea receptor 1 (SUR1). The relative order for displacement of [3H]glibenclamide in competitive binding experiments with RIN-m5F cell membranes was glibenclamide > glimepiride > repaglinide > glipizide > nateglinide >l-nateglinide > tolbutamide. The results with HEK-293/recombinant human SUR1 cells were similar with the exception that glipizide was more potent than repaglinide. Neither nateglinide nor repaglinide had any effect on the dissociation kinetics for [3H]glibenclamide, consistent with both compounds competitively binding to the glibenclamide-binding site on SUR1. Finally, the inability to measure [3H]nateglinide binding suggests that nateglinide dissociates rapidly from SUR1. Direct interaction of nateglinide with K ATPchannels in rat pancreatic β-cells was investigated with the patch-clamp method. The relative potency for inhibition of the K ATP channel was repaglinide > glibenclamide > nateglinide. Kinetics of the inhibitory effect on K ATP current showed that the onset of inhibition by nateglinide was comparab…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite the possible disadvantage of this generalized binding that may cause undesirable effects on other KATP-channel types, for example, those in the heart,312 meglitinides, namely nateglinide, have an earlier onset of action and a faster dissociation rate from the sulfonylurea receptor,313, 314, 315 resulting in a diminished risk of hypoglycemia.316”
From Pancreatic regulation of glucose homeostasis. (2016) · cites this paper as [313]
Citations
Cites
Hamill, O. P., Marty, A., Neher, E., Sakmann, B., & Sigworth, F. J. (1981) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/bf00656997 · Cited by 18,436
Enzyme structure and mechanism
Elmore, D. T. (1978) · Endeavour · doi:10.1016/0160-9327(78)90081-9 · Cited by 2,710
Cloning of the β Cell High-Affinity Sulfonylurea Receptor: a Regulator of Insulin Secretion
Aguilar-Bryan, L., Nichols, C. G., Wechsler, S. W., Clement, J. P., Boyd, A. E., González, G., Herrera-Sosa, H., Nguy, K., Bryan, J., & Nelson, D. A. (1995) · Science · doi:10.1126/science.7716547 · Cited by 1,315
Neurotransmitter receptor binding
Yamamura, H. I., Enna, S. J., & Kuhar, M. J. (1978) · Raven Press eBooks · Cited by 841
Toward Understanding the Assembly and Structure of KATPChannels
AGUILAR-BRYAN, L., CLEMENT, J. P., GONZALEZ, G., KUNJILWAR, K., BABENKO, A., & BRYAN, J. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.1.227 · Cited by 540
THE SULPHONYLUREA RECEPTOR MAY BE AN ATP-SENSITIVE POTASSIUM CHANNEL
Sturgess, N., Cook, D., Ashford, M. J., & Hales, C. N. (1985) · The Lancet · doi:10.1016/s0140-6736(85)90403-9 · Cited by 500
Schmid-Antomarchi, H., De Weille, J., Fosset, M., & Lazdunski, M. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47664-8 · Cited by 445
A New in Vitro Model for the Study of Pancreatic A and B Cells*
PIPELEERS, D. G., IN’T VELD, P. A., WINKEL, M. V. D., MAES, E., SCHUIT, F. C., & GEPTS, W. (1985) · Endocrinology · doi:10.1210/endo-117-3-806 · Cited by 341
Fuhlendorff, J., Rorsman, P., Kofod, H., Brand, C. L., Rolin, B., MacKay, P., Shymko, R., & Carr, R. D. (1998) · Diabetes · doi:10.2337/diabetes.47.3.345 · Cited by 310
Dunne, M. J., & Petersen, O. H. (1991) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/0304-4157(91)90012-l · Cited by 165
Research works printed but not linked: 2
- DeSouza, 1997, The metabolic advantages of a rapid onset/short acting insulin secretagogue on prandial glucose excursions (Abstract)., Diabetes, 46 (Suppl 1), A241
- Frøkjær-Jensen, 1992, Mechanism of action of AG-EE 623 ZW, a novel insulinotropic agent (Abstract)., Diabetologia, 35 (Suppl 1), A116
Cited by
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Pancreatic regulation of glucose homeostasis.
Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus
Rendell, M. (2004) · Drugs · doi:10.2165/00003495-200464120-00006 · Cited by 308
A review of the efficacy and safety of oral antidiabetic drugs
Stein, S. A., Lamos, E. M., & Davis, S. N. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.752813 · Cited by 305
“This review will predominantly focus on the efficacy and safety of DPP-4 inhibitors, 10.1517/14740338.2013.752813 © 2013 Informa UK, Ltd. ISSN 1474-0338, e-ISSN 1744-764X 153 All rights reserved: reproduction in whole or in part not permitted meglitinide analogs, AGIs, BAS and bromocriptine but will also address metfo…”
BackgroundInfluential
Metadata
- Authors
- Hu, S., Wang, S., Fanelli, B., Bell, P. A., Dunning, B. E., Geisse, S., Schmitz, R., & Boettcher, B. R.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2000-04
- Volume
- 293
- Issue
- 2
- Pages
- 444-452
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W4406057229
- Cited by
- 78
- References
- 34
- Citations by year
- 2025: 2 · 2024: 2 · 2021: 1 · 2019: 1 · 2018: 1 · 2017: 3 · 2016: 4 · 2015: 4 · 2014: 1 · 2013: 2 · 2012: 3
- FWCI
- 8.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- pancreatic beta cells, ATP-sensitive potassium channels, nateglinide, sulfonylureas, repaglinide, membrane binding, channel activity, glucose-stimulated insulin secretion
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pancreatic β-Cell KATP Channel Activity and Membrane-Binding Studies with Nateglinide: A Comparison with Sulfonylureas and Repaglinide. https://app.cochat.ai/papers/10.1016/s0022-3565(24)39254-7
- The paper
- Hu, S., Wang, S., Fanelli, B., Bell, P. A., Dunning, B. E., Geisse, S., Schmitz, R., & Boettcher, B. R. (2000). Pancreatic β-Cell KATP Channel Activity and Membrane-Binding Studies with Nateglinide: A Comparison with Sulfonylureas and Repaglinide. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/s0022-3565(24)39254-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.